Latest News
GSK reports positive phase III data for bepirovirsen in chronic hepatitis B
28 May 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) on Thursday reported positive phase III results for bepirovirsen, its investigational treatment for chronic hepatitis B, with pooled data from the B-Well 1 and B-Well 2 trials showi...
Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease
28 May 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that the US Food and Drug Administration (FDA) has granted priority review for its new drug application for venglustat, an investigational ora...
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network
28 May 2026 - CellCarta, a Canada-based global CRO laboratory to the biopharmaceutical industry, announced on Wednesday a strategic partnership with Sonic Healthcare USA Inc to launch the first commercial laboratory relationship in CellCarta's L...
Antengene receives Chinese clearance for Phase III study of ATG-022 in CLDN18.2+ advanced gastric/GEJ cancer
28 May 2026 - Chinese biotech company Antengene Corporation Limited (SEHK:6996) announced on Wednesday that, following review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), the company has rec...
Ribo submits Phase 2 trial application for RBD1119 to European regulator
28 May 2026 - China-based Suzhou Ribo Life Science Co Ltd (HK:06938) and Sweden-based Ribocure Pharmaceuticals AB (together 'Ribo') announced on Wednesday the submission of a Phase 2 clinical trial application to the European Medicines Agen...